Martí Carvajal, ArturoDe Sanctis, Juan BautistaDayer, MarkMartí Amarista, Cristina ElenaAlegría Barrero, EduardoMonge Martín, DianaAbd El Aziz, MohamedCorrea Pérez, AndreaNicola, SusanaParise Vasco, Juan Marcos2022-03-312022-03-3120211469-493Xhttp://hdl.handle.net/10641/2920Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the clinical benefits and harms of interleukin‐receptor antagonists and tumor necrosis factor (TNF) inhibitors for the primary and secondary prevention of atherosclerotic cardiovascular diseases. To determine whether interleukin‐receptor antagonists or TNF inhibitors, provided to people both with and without pre‐existing cardiovascular disease, are: useful in preventing adverse cardiovascular outcomes; and safe.engAtribución-NoComercial-SinDerivadas 3.0 Españahttp://creativecommons.org/licenses/by-nc-nd/3.0/es/Interleukin‐receptor antagonist and tumor necrosis factor inhibitors for theprimary and secondary prevention of atherosclerotic cardiovascular diseases.journal articleopen access10.1002/14651858.CD014741